Pharmaceutical care of a case of severe ulcerative colitis treated with vedolizumab

doi:10.19803/j.1672-8629.2022.07.19

Abstract

Abstract: Objective To explore the role of clinical pharmacists in the treatment of severe ulcerative colitis (UC) with vedolizumab and pharmaceutical care model. Methods The clinical pharmacist participated in the drug treatment of a case of severe UC, and the patient's symptoms were not significantly improved by 5-aminosalicylic acid and glucocorticoid treatment. Considering the patient's condition, the pharmacist recommended vedolizumab for treatment, and the patient was given full pharmaceutical monitoring. Results Patients with UC symptoms gradually improved after medication, and no serious adverse reactions occurred during the treatment with vedolizumab. Vedolizumab was effective in UC patients whose symptoms were not significantly improved after treatment with mesalazine and glucocorticoid. Conclusion The participation of clinical pharmacists in the formulation of treatment plans and the provision of pharmaceutical care are helpful to improve of the drug efficacy in severe UC, ensuring the safety of drugs, and improving the prognosis and quality of life of patients with UC.

Key words: ulcerative colitis, vedolizumab, pharmaceutical care, clinical pharmacists

CLC Number:

R979.1

SUN Xuelin, ZHANG Pan, HU Xin. Pharmaceutical care of a case of severe ulcerative colitis treated with vedolizumab[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 782-785.

References

[1] SATSANGI J, SILVERBERG MS, VERMEIRE S, et al.The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications[J]. Gut, 2006, 55(6): 749-753.
[2] LIU AL, LYU H, QIAN JM.Management of acute severe ulcerative colitis[J]. Chinese Journal of Gastroenterology(胃肠病学), 2019, 24(6): 321-325.
[3] WANG LB, TANG SQ.Progress in the treatment of ulcerative colitis with biological agents[J]. Chinese Journal of Postgraduates of Medicine(中国医师进修杂志), 2020, 43(12): 1141-1144.
[4] FEUERSTEIN JD, ISAACS KL, SCHNEIDER Y, et al.AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis[J]. Gastroenterology, 2020, 158(5): 1450-1461.
[5] DA SILVA BC, LYRA AC, ROCHA R, et al.Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis[J]. World J Gastroenterol, 2014, 20(28): 9458-9467.
[6] Inflammatory bowel disease group, Chinese society of gastroen-terology, Chinese medical association. Chinese consensus diagnosis and treatment of inflammatory bowel disease(Beijing, 2018)[J]. Chinese Journal of Digestion(中华消化杂志), 2018, 38(5): 292-311.
[7] DASSOPOULOS T, COHEN RD, SCHERL EJ, et al.Ulcerative colitis care pathway[J]. Gastroenterology, 2015, 149(1): 238-245.
[8] RUBIN DT, ANANTHAKRISHNAN AN, SIEGEL CA, et al.ACG clinical guideline: ulcerative colitis in adults[J]. Am J Gastroenterol, 2019, 114(3): 384-413.
[9] UNGARO R, MEHANDRU S, ALLEN PB, et al.Ulcerative colitis[J]. Lancet, 2017, 389(10080): 1756-1770.
[10] TIMMER A, PATTON PH, CHANDE N, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis[J]. Cochrane Database Syst Rev, 2016, 2016(5): CD000478.
[11] PUGLIESE D, FELICE C, PAPA A, et al.Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future[J]. Expert Rev Clin Immunol, 2017, 13(3): 223-233.
[12] ARGOLLO M, KOTZE PG, KAKKADASAM P, et al.Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(11): 702-710.
[13] LI K, TONG YL, YU XF.Nutritional support for inflammatory bowel disease[J]. International Journal of Digestive Diseases(国际消化病杂志), 2015, 35(3): 171-173, 221.
[14] GLICK LR, CIFU AS, FELD L.Ulcerative colitis in adults[J]. JAMA, 2020, 324(12): 1205-1206.
[15] LICHTENSTEIN L, RON Y, KIVITY S, et al.Infliximab-related infusion reactions: systematic review[J]. J Crohns Colitis, 2015, 9(9): 806-815.
[16] LUTHRA P, PEYRIN-BIROULET L, FORD AC.Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2015, 41(12): 1227-1236.
[17] FEAGAN BG, RUTGEERTS P, SANDS BE, et al.Vedolizumab as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med, 2013, 369(8): 699-710.
[18] NOVAK G, HINDRYCKX P, KHANNA R, et al.The safety of vedolizumab for the treatment of ulcerative colitis[J]. Expert Opin Drug Saf, 2017, 16(4): 501-507.
[19] COLOMBEL JF, SANDS BE, RUTGEERTS P, et al.The safety of vedolizumab for ulcerative colitis and Crohn's disease[J]. Gut, 2017, 66(5): 839-851.
[20] LOFTUS EV JR, COLOMBEL JF, FEAGAN BG, et al.Long-term efficacy of vedolizumab for ulcerative colitis[J]. J Crohns Colitis, 2017, 11(4): 400-411.
[21] SANDS BE, PEYRIN-BIROULET L, LOFTUS EV JR, et al.Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis[J]. N Engl J Med, 2019, 381(13):1215-1226.
[22] TAKATSU N, HISABE T, HIGASHI D, et al.Vedolizumab in the treatment of ulcerative colitis: an evidence-based review of safety, efficacy, and place of therapy[J]. Core Evid, 2020, 15: 7-20.
[23] MCLEAN LP, CROSS RK.Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis published correction appears in Expert Opin Drug Metab Toxicol[J]. Expert Opin Drug Metab Toxicol, 2016, 12(7): 833-842.